Book contents
- Case Studies: Stahl’s Essential Psychopharmacology
- Case Studies: Stahl’s Essential Psychopharmacology
- Copyright page
- Contents
- Introduction
- Contributors
- List of icons
- Abbreviations
- Case 1: Usage of esketamine spray for treatment-resistant major depressive disorder (MDD)
- Case 2: The man who is confused about his identity
- Case 3: Propane, shattered glass, and parasites
- Case 4: Hit by a car
- Case 5: Caring for the whole person
- Case 6: The man whom clozapine (Clozaril) could not touch
- Case 7: Where did her period go?
- Case 8: To dopamine or not to dopamine, that is the question
- Case 9: The one that came out of nowhere
- Case 10: Darth Vaper strikes again
- Case 11: First-time Mom’s struggle with postpartum post-traumatic stress disorder (PTSD)
- Case 12: Why so down?
- Case 13: It’s confusing, isn’t it?
- Case 14: The adolescent who just can’t stay awake
- Case 15: The lady with bipolar disorder (BP), borderline personality disorder (BPD), and myasthenia gravis (MG)
- Case 16: Spending money does not make a bipolar diagnosis
- Case 17: Pain makes me anxious, and anxiety gives me pain
- Case 18: The woman who couldn’t focus
- Case 19: The gentleman with sudden onset of akathisia on clozapine (Clozaril)
- Case 20: The pregnancy blues
- Case 21: The menopause blues
- Case 22: The lady who felt “funny” on the medication
- Case 23: Two ladies with bruises
- Case 24: The lady who was afraid for her kids
- Case 25: The woman whose kidneys could not handle lithium
- Case 26: The gentleman who was sober and could not focus
- Case 27: When the music does not stop
- Case 28: The man who tried to get it right
- Index of drug names
- Index of case studies
- References
Case 1: - Usage of esketamine spray for treatment-resistant major depressive disorder (MDD)
Published online by Cambridge University Press: 03 April 2024
By
Book contents
- Case Studies: Stahl’s Essential Psychopharmacology
- Case Studies: Stahl’s Essential Psychopharmacology
- Copyright page
- Contents
- Introduction
- Contributors
- List of icons
- Abbreviations
- Case 1: Usage of esketamine spray for treatment-resistant major depressive disorder (MDD)
- Case 2: The man who is confused about his identity
- Case 3: Propane, shattered glass, and parasites
- Case 4: Hit by a car
- Case 5: Caring for the whole person
- Case 6: The man whom clozapine (Clozaril) could not touch
- Case 7: Where did her period go?
- Case 8: To dopamine or not to dopamine, that is the question
- Case 9: The one that came out of nowhere
- Case 10: Darth Vaper strikes again
- Case 11: First-time Mom’s struggle with postpartum post-traumatic stress disorder (PTSD)
- Case 12: Why so down?
- Case 13: It’s confusing, isn’t it?
- Case 14: The adolescent who just can’t stay awake
- Case 15: The lady with bipolar disorder (BP), borderline personality disorder (BPD), and myasthenia gravis (MG)
- Case 16: Spending money does not make a bipolar diagnosis
- Case 17: Pain makes me anxious, and anxiety gives me pain
- Case 18: The woman who couldn’t focus
- Case 19: The gentleman with sudden onset of akathisia on clozapine (Clozaril)
- Case 20: The pregnancy blues
- Case 21: The menopause blues
- Case 22: The lady who felt “funny” on the medication
- Case 23: Two ladies with bruises
- Case 24: The lady who was afraid for her kids
- Case 25: The woman whose kidneys could not handle lithium
- Case 26: The gentleman who was sober and could not focus
- Case 27: When the music does not stop
- Case 28: The man who tried to get it right
- Index of drug names
- Index of case studies
- References
Summary
How are the antidepressant effects of esketamine (Spravato) pharmacodynamically mediated?
Keywords
major depressive disorder (MDD)treatment resistanceaugmentationcombinationantidepressant drugsserotonin syndromecariprazine (Vraylar)dextromethorphan / quinidine sulfate (Nuedexta)esketamine (Spravato)L-methylfolate (Deplin)levomilnacipran (Fetzima)lisdexamfetamine (Vyvanse)n-acetylcysteine (NAC)vortioxetine (Trintellix)
- Type
- Chapter
- Information
- Case Studies: Stahl's Essential Psychopharmacology , pp. 1 - 20Publisher: Cambridge University PressPrint publication year: 2024
References
Abdallah, CG, Adams, TG, Kelmendi, B, et al. Ketamine’s mechanism of action: a path to rapid‐acting antidepressants. Depress Anxiety 2016; 33:689–97CrossRefGoogle ScholarPubMed
Bahji, A, Vazquez, GH, Zarate, CA, Jr. Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis. J Affect Disord 2021; 278:542–55CrossRefGoogle ScholarPubMed
Berk, M, Singh, A, Kapczinski, F. When illness does not get better: do we need a palliative psychiatry? Acta Neuropsychiatr 2008; 20:165–6CrossRefGoogle Scholar
Lauterbach, EC. An extension of hypotheses regarding rapid-acting, treatment-refractory, and conventional antidepressant activity of dextromethorphan and dextrorphan. Med Hypotheses 2012; 78:693–702CrossRefGoogle ScholarPubMed
Phillips, JL, Norris, S, Talbot, J, et al. Single, repeated, and maintenance ketamine infusions for treatment-resistant depression: a randomized controlled trial. Am J Psychiatry 2019; 176:401–9CrossRefGoogle ScholarPubMed
Popova, V, Daly, EJ, Trivedi, M, et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am J Psychiatry 2019; 176:428–38CrossRefGoogle ScholarPubMed
Sial, OK, Parise, EM, Parise, LF, et al. Ketamine: the final frontier or another depressing end? Behav Brain Res 2020; 383:112508CrossRefGoogle ScholarPubMed
Singh, JB, Fedgchin, M, Daly, EJ, et al. A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression. Am J Psychiatry 2016; 173:816–26CrossRefGoogle ScholarPubMed
Sleigh, J, Harvey, M, Voss, L, et al. Ketamine – more mechanisms of action than just NMDA blockade. Curr Anaesth Crit Care 2014; 4:76–81Google Scholar
Stahl, SM. Treatments for mood disorders: so-called “antidepressants” and “mood stabilizers. In Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications, 5. Cambridge: Cambridge University Press, 2021, 283–358CrossRefGoogle Scholar
Taylor, CP, Traynelis, SF, Siffert, J, et al. Pharmacology of dextromethorphan: relevance to dextromethorphan/quinidine (Nuedexta®) clinical use. Pharmacol Ther 2016; 164:170–82CrossRefGoogle ScholarPubMed
Trachsel, M, Irwin, SA, Biller-Andorno, N, et al. Palliative psychiatry for severe persistent mental illness as a new approach to psychiatry? Definition, scope, benefits, and risks. BMC Psychiatry 2016; 16:260CrossRefGoogle ScholarPubMed
Williams, NR, Heifets, BD, Bentzley, BS, et al. Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism. Mol Psychiatry 2019; 24:1779–86CrossRefGoogle ScholarPubMed
Yuen, EY, Wei, J, Liu, W, et al. Repeated stress causes cognitive impairment by suppressing glutamate receptor expression and function in prefrontal cortex. Neuron 2012; 73:962–77CrossRefGoogle ScholarPubMed
Zhao, Y, Sun, L. Antidepressants modulate the in vitro inhibitory effects of propofol and ketamine on norepinephrine and serotonin transporter function. J Clin Neurosci 2008; 15:1264–9CrossRefGoogle ScholarPubMed